脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究

Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

目的探讨脾多肽对三阴性乳腺癌术后辅助化学药物治疗(以下简称化疗)患者的临床疗效。方法将2014年1月至2017年12月间收治的80例三阴性乳腺癌患者采用数字表法随机分为对照组(n=40)和试验组(n=40),对照组采用常规的根治手术加术后辅助化疗,试验组在对照组的基础上加用脾多肽注射液,比较试验组和对照组患者的临床疗效和免疫功能。结果治疗后,试验组与对照组相比,Karnofsky功能状态评分明显增高(F=5.793,P=0.018),CD4+(t=5.337,P<0.001)、CD8+(t=9.874,P<0.001)、自然杀伤细胞(natural killer cell,NK)(t=-7.460,P<0.001)的比例及Treg细胞(t=7.113,P<0.001)都有不同程度地增高。试验组的无进展生存期(progress-free survival period,PFS)比对照组长,两组差异有统计学意义(P<0.05)。两组的上肢淋巴水肿率差异无统计学意义(P>0.05)。结论脾多肽注射液可明显提高患者免疫功能,促进生活质量改善与提高,在临床治疗领域具备进一步推广价值。

Objective To explore the effect of lineal polypeptide injection combined with chemotherapy on the clinical efficacy in patients with triple-negative breast cancer.Methods Eighty patients with triple-negative breast cancer at Shanxi Provincial Cancer Hospital from January 2014 to December 2017 were enrolled in the study and randomly divided into control group with 40 cases and experimental group with 40 cases.In comparison with the control group treated with conventional postoperative chemotherapy,the experimental group was given the additional lienal polypeptide injection on the basis of the control group.The immunological function and clinical efficacy were compared.Results After treatment,the Karnofsky functional status score of the experimental group was significantly higher than that of the control group(F=5.793,P=0.018),and the proportion of CD4+(t=5.337,P<0.001),CD8+(t=9.874,P<0.001),natural killer cell(NK)(t=-7.460,P<0.001)and Treg cells(t=7.113,P<0.001)were all increased to different degrees.The progress-free survival period(PFS)of the experimental group was longer than that of the control group,and the difference between the two groups was statistically significant(P<0.05).However,there was no statistically significant difference in the rate of upper limb lymphedema(P>0.05).Conclusion Lineal polypeptide injection can effectively improve the immune function and enhance the general life of triple-negative breast cancer patients.